The Food and Drug Administration on Wednesday defended its rejection of Moderna’s mRNA-based flu vaccine application, saying the company’s clinical trial design put patients at risk The Food and Drug Administration on Wednesday defended its rejection of Moderna’s mRNA-based flu vaccine application, saying the company’s clinical trial design put patients at risk
FDA defends its decision not to review Moderna’s mRNA flu shotFDA defends its decision not to review Moderna’s mRNA flu shot
